FDCDDQ
CRSP icon

Federation des caisses Desjardins du Quebec’s CRISPR Therapeutics CRSP Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111K Sell
2,035
-772
-28% -$40.7K ﹤0.01% 1734
2026
Q1 		$134K Buy
2,807
+484
+21% +$25.5K ﹤0.01% 1619
2025
Q4 		$122K Buy
2,323
+69
+3% +$4.13K ﹤0.01% 1615
2025
Q3 		$146K Buy
2,254
+182
+9% +$10.4K ﹤0.01% 1556
2025
Q2 		$101K Buy
2,072
+250
+14% +$9.68K ﹤0.01% 1368
2025
Q1 		$62K Sell
1,822
-41
-2% -$1.74K ﹤0.01% 1427
2024
Q4 		$73.3K Buy
1,863
+882
+90% +$41.6K ﹤0.01% 1334
2024
Q3 		$46.1K Sell
981
-57
-5% -$2.89K ﹤0.01% 1427
2024
Q2 		$56.1K Buy
1,038
+7
+0.7% +$405 ﹤0.01% 1368
2024
Q1 		$70.3K Buy
1,031
+231
+29% +$16.5K ﹤0.01% 1317
2023
Q4 		$50.1K Sell
800
-101
-11% -$5.58K ﹤0.01% 1308
2023
Q3 		$40.9K Hold
901
– – ﹤0.01% 1365
2023
Q2 		$50.6K Sell
901
-42
-4% -$2.38K ﹤0.01% 1324
2023
Q1 		$42.7K Buy
943
+425
+82% +$20.6K ﹤0.01% 1370
2022
Q4 		$21.1K Sell
518
-325
-39% -$17.2K ﹤0.01% 1667
2022
Q3 		$55.1K Buy
843
+100
+13% +$7.25K ﹤0.01% 1488
2022
Q2 		$45.2K Sell
743
-85
-10% -$5K ﹤0.01% 1544
2022
Q1 		$52K Sell
828
-155
-16% -$9.73K ﹤0.01% 1574
2021
Q4 		$74.5K Sell
983
-55
-5% -$4.8K ﹤0.01% 1474
2021
Q3 		$116K Sell
1,038
-220
-17% -$27.6K ﹤0.01% 1350
2021
Q2 		$204K Sell
1,258
-31
-2% -$3.77K ﹤0.01% 1178
2021
Q1 		$157K Buy
1,289
+179
+16% +$27K ﹤0.01% 1190
2020
Q4 		$170K Buy
1,110
+107
+11% +$12.6K ﹤0.01% 1103
2020
Q3 		$83.9K Sell
1,003
-3,298
-77% -$293K ﹤0.01% 1109
2020
Q2 		$317K Sell
4,301
-20,737
-83% -$1.21M ﹤0.01% 739
2020
Q1 		$1.07M Buy
25,038
+23,558
+1,592% +$1.22M 0.02% 505
2019
Q4 		$90.1K Sell
1,480
-90
-6% -$4.91K ﹤0.01% 1351
2019
Q3 		$64.4K Hold
1,570
– – ﹤0.01% 1409
2019
Q2 		$73.9K Sell
1,570
-30
-2% -$1.2K ﹤0.01% 1377
2019
Q1 		$57.2K Sell
1,600
-100
-6% -$3.46K ﹤0.01% 1287
2018
Q4 		$48.6K Sell
1,700
-2,630
-61% -$91.4K ﹤0.01% 1291
2018
Q3 		$192K Sell
4,330
-300
-6% -$15.7K ﹤0.01% 1033
2018
Q2 		$272K Buy
4,630
+3,530
+321% +$201K ﹤0.01% 974
2018
Q1 		$50.3K Buy
1,100
+850
+340% +$35.1K ﹤0.01% 1327
2017
Q4 		$5.87K Hold
250
– – ﹤0.01% 1841
2017
Q3 		$4.47K Sell
250
-550
-69% -$9.97K ﹤0.01% 1844
2017
Q2 		$12.8K Buy
800
+152
+23% +$2.51K ﹤0.01% 1673
2017
Q1 		$14.1K Buy
+648
New +$12.7K ﹤0.01% 1364

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's CRSP Position: Q2 2026 in Review

Federation des caisses Desjardins du Quebec reduced its CRISPR Therapeutics (CRSP) stake by 28% in Q2 2026, selling an estimated $40.7K and leaving 2,035 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #1734.

Federation des caisses Desjardins du Quebec first reported a position in CRSP in Q1 2017 and has held it in 38 quarters since. The position peaked at $1.07M in Q1 2020. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Federation des caisses Desjardins du Quebec held 2,035 shares of CRISPR Therapeutics worth $111K as of Q2 2026.
  • Federation des caisses Desjardins du Quebec sold 772 CRISPR Therapeutics shares in Q2 2026, an estimated $40.7K.
  • CRISPR Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q2 2026, its #1734 holding.
  • Federation des caisses Desjardins du Quebec first reported a position in CRISPR Therapeutics in Q1 2017 and has held it in 38 quarters since.
  • Federation des caisses Desjardins du Quebec's CRISPR Therapeutics position peaked at $1.07M in Q1 2020.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2026, filed 14 Aug 2026.